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Abstract
Pregnane X receptor (PXR) is known to function as a xenobiotic sensor to regulate xenobiotic metabolism through selective
transcription of genes responsible for maintaining physiological homeostasis. Here we report that the activation of PXR by
pregnenolone 16a-carbonitrile (PCN) in AKR/J mice can prevent the development of high-fat diet-induced obesity and
insulin resistance. The beneficial effects of PCN treatment are seen with reduced lipogenesis and gluconeogenesis in the
liver, and lack of hepatic accumulation of lipid and lipid storage in the adipose tissues. RT-PCR analysis of genes involved in
gluconeogenesis, lipid metabolism and energy homeostasis reveal that PCN treatment on high-fat diet-fed mice reduces
expression in the liver of G6Pase, Pepck, Cyp7a1, Cd36, L-Fabp, Srebp, and Fas genes and slightly enhances expression of
Cyp27a1 and Abca1 genes. RT-PCR analysis of genes involved in adipocyte differentiation and lipid metabolism in white
adipose tissue show that PCN treatment reduces expression of Pparc2, Acc1, Cd36, but increases expression of Cpt1b and
Ppara genes in mice fed with high-fat diet. Similarly, PCN treatment of animals on high-fat diet increases expression in
brown adipose tissue of Ppara, Hsl, Cpt1b, and Cd36 genes, but reduces expression of Acc1 and Scd-1 genes. PXR activation
by PCN in high-fat diet fed mice also increases expression of genes involved in thermogenesis in brown adipose tissue
including Dio2, Pgc-1a, Pgc-1b, Cidea, and Ucp-3. These results verify the important function of PXR in lipid and energy
metabolism and suggest that PXR represents a novel therapeutic target for prevention and treatment of obesity and insulin
resistance.
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Introduction
Pregnane X receptor (PXR; steroid and xenobiotic receptor or
SXR) is a nuclear hormone receptor activated by xenobiotics as
well as by diverse steroids and their metabolites [1–3]. PXR is
known to induce, upon ligand binding, the expression of genes
coding for phase I (Cyp3a11, CYP3A4, Cyp2b10) and phase II
(Sult2a1, UDP-glucuronosyltransferase and GST) enzymes and
drug transporters (MDR1) [4]. A good example of PXR-mediated
regulation is transcription of CYP3A4 gene encoding an enzyme
responsible for the metabolism of more than 50% of clinical drugs
[5].
In recent years, a number of clinical observations using PXR
activators have linked PXR to lipid metabolism and energy
homeostasis. Notably, treating with rifampicin, a PXR ligand, can
influence lipid metabolism [6]. Similarly, treating children with
antiepileptic drugs carbamazipine and phenobarbital for an
extended time, could activate PXR and increase cholesterol levels
[7]. Transgenic mice expressing constitutively activated PXR
showed hepatic steatosis [8]. However, PXR also modulated sterol
regulatory element binding protein 1 (SREBP-1) by inducing Insig-
1 expression, resulting in decreased levels of active SREBP-1 and
reduced triglyceride synthesis [9]. Although additional studies are
needed to resolve the seemingly contradictory effects of PXR
activation in lipid homeostasis, the results from these studies firmly
establish the role of PXR in regulating lipid and energy
homeostasis at multiple levels.
Confirmation of the functional role of PXR in lipid metabolism
has provided an opportunity to explore the mechanisms through
which PXR agonists may impact energy homeostasis. Therefore,
in this study, a mouse model was used to assess the effect of PXR
activation on prevention of high-fat diet-induced obesity and
insulin resistance. PXR activation was achieved by intraperitoneal
injections of pregnenolone 16 a-carbonitrile (PCN), a mouse
specific PXR activator. In AKR/J mice we demonstrate that PXR
activation is capable of regulating lipid metabolism and energy
expenditure, and consequently, preventing the development of
high-fat diet-induced obesity and insulin resistance.
Results
PXR Activation Prevented Animals from Development of
High-fat Diet-induced Obesity
To explore whether PXR plays an important role in the
development of high-fat diet-induced obesity, 4-week old male
AKR/J mice were fed a high-fat diet or regular chow as a control
for 7 weeks, and simultaneously treated with PCN (50 mg/kg,
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38734twice weekly) or vehicle (DMSO). AKR/J mice are an obesity-
prone inbred strain which gain body weight and fat more quickly
compared to the C57BL/6J strain when fed with high-fat diet
[10,11]. They are also more insulin resistant [12] and therefore,
are commonly used as a model for research on diet-induced
obesity and obesity-related insulin resistance. As shown in
Figure 1A, PCN treatment did not affect the growth rate of mice
on regular chow. However, for animals fed with high-fat diet, PCN
treatment resulted in a significant decrease in growth rate as
compared to those treated with DMSO. A statistical difference was
evidenced as early as the first 3 weeks of high-fat diet feeding. After
7 weeks, the average body weight of PCN treated animals was
28.661.3 g, 16.7 g less than the DMSO treated control groups at
45.362.5 g. There was no statistical difference between PCN-
treated animals on high-fat diet and those on regular chow. The
difference in body weight between DMSO-treated animals on a
high-fat diet and the remaining animals is largely due to the
difference in fat mass (Figure 1B). An approximately 60%
reduction in fat mass was seen in PCN-treated animals fed with
high-fat diet as compared to those of DMSO injected controls.
There was no statistical difference in lean mass among animals fed
with either regular chow or high-fat diet. When mice were fed with
high-fat diet, the food intake per mouse per day in the PCN-
treated group was lower when compared to DMSO-treated
controls (Figure 1C). However, the caloric intake by PCN-treated
animals appears slightly higher when corrected for total body
weight (Figure 1D).
In order to confirm whether the effects of PCN treatment seen
in affected animals is correlated to PXR activation, the transcript
levels of PXR target genes were measured. Results in Figure 2
show that PCN treatment significantly enhanced the expression of
genes coding for enzymes involved in drug metabolism including
Cyp3a11, Cyp2b10, Sulat2a1 and Mdr1a, regardless of whether
animals were on regular chow or on a high-fat diet. However,
Figure 2 also showed that the high-fat diet is also capable of
elevating gene expression for Cyp3a11 and Cyp2b10. Since CYP3A
and CYP2B genes can be regulated by both PXR and CAR [13],
we included in the study of Cyp1a2, a target gene specific to CAR
[14]. No increase in Cyp1a2 mRNA level in PCN treated animals,
whether on regular chow or a high-fat diet, suggests that PCN
effect observed is mediated by PXR activation. This result agrees
with the previous report that the mRNA level of Cyp2b10 was
elevated in genetic ob/ob male mice [15]. Considered together,
Figure 1. PCN treatment protected mice against high-fat diet–induced obesity. Four-week-old male AKR/J mice were fed with high-fat diet
or regular chow for 7 weeks with twice weekly injections of PCN (50 mg/kg, IP) or DMSO (carrier solution). A, growth curve; B, fat and lean mass; C,
food intake; and D, calculated ratio of caloric intake/body weight. Each data point represents the average 6 SD of 4 animals in each group. #P,0.05,
##P,0.01 compared to chow-DMSO group; *P,0.05, **P,0.01 compared to high-fat diet-DMSO group.
doi:10.1371/journal.pone.0038734.g001
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protection animals against high-fat diet-induced obesity.
PCN Treatment Improved Insulin Sensitivity of Animals
Fed with High-fat Diet
Obesity is frequently associated with insulin resistance, a
characteristic of type-2 diabetes. Next, we investigated whether
PXR activation would affect glucose homeostasis. Glucose
tolerance tests (Figure 3A) and calculated area under the curve
(AUC) (Figure 3B) showed that there was no difference in glucose
clearance among animals fed with regular chow and those fed with
high-fat diet plus PCN treatment. The high-fat diet-fed control
animals (treated with DMSO) exhibited a much slower clearance
rate of intraperitoneally injected glucose. Protection against diet-
induced insulin resistance was also confirmed using an insulin
tolerance test (ITT). Results in Figure 3C show rapid reduction of
glucose concentration in serum upon insulin injection in animals
fed on regular chow or PCN treated animals fed with high-fat diet,
as compared with DMSO-treated control on high-fat diet. Similar
patterns were obtained in insulin level in serum (Figure 3D) and by
HOMA-IR (Figure 3F). These results demonstrate that PCN
treatment prevents the progression of insulin resistance in animals
on high-fat diet.
To investigate how PCN treatments maintain the insulin
sensitivity in animals fed with high-fat diet, we measured the
expression of genes involved in hepatic gluconeogenesis after mice
were sacrificed. Results (Figure 3E) from real time PCR reveal a
marked increase in the amount of transcript for phosphoenolpyr-
uvate carboxykinase (Pepck) and glucose-6-phosphatase (G6Pase)
genes in the high-fat diet group treated with DMSO, concordant
with hyperglycemia and hyperinsulinemia. Although PCN slightly
increased the expression levels of both genes in mice fed with
regular food, PCN treatment had a significantly lower high-fat
diet-induced increase in gene expression of Pepck and G6Pase by
73% and 31%, respectively. It is noteworthy that the Pepck
promoter contains multiple transcription factor binding sites for
rapid transcription regulation [16]. In contrast, further studies are
needed to demonstrate whether PCN plays a role in regulating the
activity of PEPCK enzymes. Overall, these results suggest that
inhibition of high-fat diet-induced gluconeogenesis by PCN is
responsible, at least in part, for maintaining insulin sensitivity.
Inhibition of high-fat diet-induced lipid accumulation by
PCN treatment
Hepatic lipid accumulation has a strong correlation with obesity
and insulin resistance [17]. We further evaluated the effect of PCN
on hepatic cholesterol and lipid metabolism. H&E stained liver
sections showed a normal liver structure of mice on regular chow
with or without PCN treatment (Figures 4A and 4B). However,
there was extensive hepatocyte vacuolation in animals fed with a
high-fat diet (Figure 4C), reflecting intrahepatic fat accumulation
in high-fat diet-fed mice. In contrast, PCN treatment efficiently
ameliorated lipids accumulation in hepatocytes (Figure 4D). Oil
Red O staining of liver sections confirmed no oil accumulation in
animals on regular chow (Figures E and F), but a massive
accumulation of fatty components in the livers of mice on a high-
fat diet (Figure 4G), and significantly less oil accumulation in the
PCN-treated group (Figure 4H).
To determine how PCN reduces the excess lipid accumulation
in the liver of animals on a high-fat diet, we performed analyses on
the expression profiles of genes that are involved in cholesterol and
lipids metabolism. As shown in Figure 5A, PCN treatment
inhibited the cholesterol 7 a-hydroxylase (Cyp7a1) gene expression
on regular chow and on high-fat diet, in agreement with the results
from previous studies [18,19]. PCN did not affect the expression of
the 3-hydroxy-3-methylglutaryl coenzyme A reductase (Hmgcr)
gene, a key enzyme in cholesterol biosynthesis. Compared to
animals on regular chow, PCN treatment of animals on high-fat
Figure 2. Up-regulation of PXR target genes by PCN treatment. At end of the 7-week treatment with PCN, mice were sacrificed 4 h later and
livers were taken and frozen at -80uC. Hepatic expressions of selected genes were measured by real-time PCR analysis. #P,0.05, ##P,0.01
compared to chow-DMSO group; *P,0.05, **P,0.01 compared to high-fat diet-DMSO group. Abbreviations: Cyp3a11, cytochrome P450, family 3,
subfamily a, polypeptide 11 gene; Cyp2b10, cytochrome P450, family 2, subfamily b, polypeptide 10 gene; Sult2a1, cytosolic sulfotransferase 2A1
gene; and Mdr1a, multi-drug-resistance 1a gene. Each data point represents the average 6 SD of 4 animals in each group.
doi:10.1371/journal.pone.0038734.g002
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ATP-binding cassette transporter Abca1 (Figure 5B), the genes
involving cholesterol efflux. PCN treatment slightly reduced
transcript levels of the Abcg1 gene.
The most striking changes were seen in genes that regulate
lipogenesis and lipid uptake. CD36 is responsible for the
transport of long-chain fatty acids into the adipose and hepatic
tissues [20–22]. Increased hepatic CD36 activity is critical for
Figure 3. Effect of PCN treatment on glucose tolerance, insulin sensitivity, serum concentration of insulin, and mRNA level of
G6Pase and Pepck. Animals at the end of the 7-week treatments were fasted overnight for glucose tolerance tests, or fasted for 4 h for insulin
sensitivity tests. A, time-dependent blood concentration of glucose upon IP injection of glucose (2 g/kg); B, area under the curve from glucose
tolerance test in A; C, time dependent glucose concentration upon IP injection of insulin; D, insulin levels at the end of the 7-week feeding with high-
fat diet and regular chow food with or without PCN treatment; E, relative mRNA level of G6Pase and Pepck in mouse liver at the end of animal feeding
and PCN treatment; and F, HOMA-IR values calculated based on formula: Glucose (mg/dl) 6Insulin ( mU/ml)/405. Each data point represents the
average 6 SD of 4 animals in each group. #P,0.05, ##P,0.01 compared to chow-DMSO group; *P,0.05, **P,0.01 compared to high-fat diet-
DMSO group.
doi:10.1371/journal.pone.0038734.g003
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Figure 5C showed that Cd36 was up-regulated 5.7-fold in high-
fat diet-fed mice compared to that of mice on regular food.
However, PCN treatment attenuated the high-fat diet-induced
transcription of Cd36 by 55%. At the same time, PCN also
decreased the mRNA level of liver fatty acid binding protein (L-
FABP) when mice were fed with a high-fat diet. PCN treatment
significantly inhibited high-fat diet-induced increase of Srebp-1c
gene expression and its target gene responsible for fatty acid
synthase (Fas) by 85% and 50%, respectively. Both SREBP-1c
and FAS are key regulatory enzymes in the lipogenetic pathway
(Figure 5D). These data suggested that decreased hepatic
lipogenesis and fatty acid uptake could alleviate high-fat diet-
induced hepatic fat accumulation.
PCN Treatment Prevented Adiposity in White Adipose
Tissue (WAT) and Brown Adipose Tissue (BAT) of Animals
Fed with High-fat Diet
Excessive deposition of lipids in adipose tissues is one of the
major characteristics in obesity. Comparing to that of animals on
regular chow (Figures 6A and 6B), the size of adipocytes in WAT
of high-fat diet-fed animals is significantly larger (Figure 6C).
However, there is no difference between animals on a regular
chow (Figures 6A and 6B) and those treated with PCN when on a
high-fat diet (Figure 6D). Reduction of lipids accumulation is even
more prominent in BAT. Larger adipocytes are evidenced in
animals on a high-fat diet (Figure 6G) as compared to those of
animals either on regular chow (Figures 6E and 6F) or treated with
PCN when on high-fat diet (Figure 6H).
Quantitative PCR was performed on total RNAs extracted
from WAT and BAT to examine the PCN effect on
transcription of adipocyte protein 2 (aP2), CCAAT/enhancer
binding protein a (C/Ebpa) and Pparc2 gene in high-fat diet-fed
mice. Results in Figure 7A show that in WAT, PCN reduces
the expression of Pparc2. PCN induces a significant reduction in
mRNA level of C/EBPa in animals fed with regular chow but
not in high-fat diet-fed animals. Previous studies indicated that
PXR is a positive regulator of PPARc in the liver [25].
However, PPARc2 is mostly expressed in the adipose tissue [26].
Further study is needed to elucidate the mechanism of the
differential regulation. PCN also did not alter the expression of
the same set of genes in BAT (Figure 7D), suggesting that the
reduction in total fat mass may be a result from less triglyceride
accumulation rather than a reduced number of adipocytes. At
the same time, high-fat diet feeding did not induce lipogenesis
in WAT and BAT (Figures 7B, 7E). However, lipolysis and b-
oxidization is significantly enhanced by PCN in high-fat diet-fed
mice, as evidenced by elevation of gene expression of Ppara,
Cpt1b and Hsl in WAT and BAT (Figures 7C, 7F). In WAT,
PCN lowered the high-fat diet-induced CD36 expression by
60%. In contrast, PCN up-regulated the mRNA level of Cd36
in BAT, suggesting difference between WAT and BAT in lipid
metabolism.
PCN Treatment Increased Expression of Genes Involved
in Energy Expenditure in High-fat Diet-fed Mice
BAT plays an important role in thermogenesis [27–29]. To
further analyze the potential mechanisms of PCN effect, we
measured the changes of body temperature when these animals
were exposed to 4uC. Results in Figure 8A show that mice treated
with PCN had a much slower decrease in body temperature than
the DMSO-treated control, suggesting that activation of PXR
enhanced the thermogenic activity in BAT. At the molecular level,
PCN treatment significantly enhanced the transcription of genes
that are critical for cellular thermogenesis including Dio2, Pgc-1a,
Pgc-1b, Cidea, and Ucp-3. No difference was seen in Ucp-2 mRNA
level of high-fat diet-fed animals with or without PCN treatment
(Figure 8B). These results suggest that PCN treatment increased
energy expenditure in BAT.
Discussion
In this study, we demonstrate that activation of PXR by PCN
prevented development of high-fat diet-induced obesity and
Figure 4. Effect of PCN treatment on hepatic accumulation of lipids. At the end of the 7-week treatment, animals were sacrificed; liver
sections were made and stained with H&E (A–D) or Oil Red O (E–H). A and E, animals on regular chow and treated with DMSO; B and F, animals on
regular chow and treated with PCN; C and G, animals on high-fat diet and treated with DMSO; and D and H; animals on high-fat diet and treated
with PCN. Scale bar, 20 mm.
doi:10.1371/journal.pone.0038734.g004
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accumulation (Figures 1, 3, 4). The beneficial effect of PCN
treatment was achieved by inhibition of lipogenesis and gluco-
neogenesis in the liver (Figures 3E and 5) as well as inhibition of
lipid uptake in liver and WAT (Figures 5c and 7c), by enhanced
lipolysis in adipose tissue (Figures 7C, 7F), and by increased
peripheral fat mobilization and energy expenditure in BAT
(Figure 8).
The hypoglycemic effect after PCN treatment on animals on
high-fat diet was mediated by inhibiting diet-induced increase of
PEPCK and G6Pase (Figure 3E), two key enzymes in
gluconeogenesis, in agreement with previous reports [30]. It is
possible that activated PXR directly interacts with FoxO1, one
of the transcription factors that plays a critical role in lipid
metabolism and gluconeogenesis in the liver [31], and prevents
FoxO1 from binding to IRS, resulting in the suppression of
G6Pase and Pepck1 gene expression [32]. In addition, inhibition
of lipid accumulation by PCN may also contribute indirectly in
maintenance of glucose homeostasis because lipotoxicity in the
liver and pancreas exerts an important function in type-2
diabetes [33]. It is still unknown, however, how PCN improves
obesity-induced insulin resistance. Decrease in fat accumulation
in WAT may benefit improved insulin sensitivity. It’s well
known that adipocytes in WAT release significant amounts of
pro-inflammatory cytokines such as TNFa, IL-6 and IL-1.
Obesity also resulted in more macrophage infiltration in adipose
tissue [34]. These pro-inflammatory cytokines and chronic
inflammation in fat are major factors in causing the whole-
body obesity-related insulin resistance [35]. Our unpublished
data show that PCN decreases macrophage accumulation and
pro-inflammatory cytokine release in adipose tissue. In addition,
the NFkB pathway plays a crucial role in production of pro-
inflammatory cytokines. While activation of PXR inhibits the
Figure 5. Effect of PCN treatment on expression of genes involved in lipogenesis and lipids uptake. Four h after treatment, mice were
sacrificed and livers were harvested. The expression of genes involved in the cholesterol metabolism (A, B), lipids metabolism (C) and lipids uptake
(D) were measured by real-time PCR. Each data point represents the average 6 SD of 4 animals in each group. #P,0.05, ##P,0.01 compared to
chow-DMSO group; *P,0.05, **P,0.01 compared to high-fat diet-DMSO group. Abbreviations: Cyp7a1, cholesterol 7 alpha-hydroxylase gene;
HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase gene; Cyp27a1, sterol 27-hydroxylase; Abca1, Abcg1, ATP-binding cassette transporter A1
and G1; SREBP-1c, sterol regulatory element-binding protein 1c; FAS, fatty acid synthase; Scd-1, stearoyl CoA desaturase 1; and L-FABP, liver fatty-
acid-binding protein.
doi:10.1371/journal.pone.0038734.g005
Activation of Pregnane X Receptor to Block Obesity
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38734Figure 6. Effect of PCN treatement on lipid accumulation in adipose tissues. At the end of the 7-week treatment, animals were sacrificed,
white (A–D) and brown (E–H) adipocyte tissues were collected and stained with H&E. A and E, animals on regular chow and treated with DMSO; B
and F, animals on regular chow and treated with PCN; C and G, animals on high-fat diet and treated with DMSO; and D and H; animals on high-fat
diet and treated with PCN. Scale bar, 20 mm.
doi:10.1371/journal.pone.0038734.g006
Figure 7. Effect of PCN treatment on expression of genes involved in adipocyte differentiation and lipid metabolism. At the end of
the 7-week treatment animals were treated with PCN or DMSO (carrier solution) and sacrificed 4 h later. WAT and BAT tissues were harvested and
total RNA was extracted. Relative mRNA level of genes involved in adipose differentiation in WAT (A) and BAT (D) tissue; genes involved in the
lipogenesis in WAT (B) and BAT (E); and genes involved in lipids uptake and b-oxidation in WAT (C) and BAT (F). Each data point represents the
average 6 SD of 4 animals in each group. #P,0.05, ##P,0.01 compared to chow-DMSO group; *P,0.05, **P,0.01 compared to high-fat diet-
DMSO group. Abbreviations: aP2, adipocyte protein 2 gene; C/EBPa, CCAAT/enhancer binding protein alpha gene; PPARc, peroxisome proliferator-
activated receptor gamma gene; ACC1, acetyl-CoA carboxylases 1 gene; CPT1b, carnitine palmitoyltransferase 1b gene; and HSL, hormone-sensitive
lipase gene.
doi:10.1371/journal.pone.0038734.g007
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through inhibiting obesity-induced chronic inflammation.
Results shown in Figures 4 and 6 demonstrate that PCN-
mediated PXR activation significantly prevented the lipid storage
in adipose tissue and the liver. Except for inhibiting lipogenesis, a
more important characteristic of PXR in diet-induced obesity was
reduction of lipid uptake in liver and adipose, confirmed by
inhibiting up-regulation of Cd36 expression by high-fat diet. Cd36
codes for a scavenger receptor with broad ligand specificity.
Activation of Cd36 facilitates free fatty acid uptake from circulation
and also contributes to obesity, hepatic steatosis and type-2
diabetes [24,37]. Previous studies show that Cd36 is a shared
transcriptional target of LXR, PXR and PPARc in their
regulation of lipid homeostasis [25]. In the PXR-transgenic mice,
Cd36 was up-regulated when fed with regular chow, which is
different from our result obtained from the high-fat diet-fed mice.
In our opinion, as in drug metabolism, PXR may serve as a
‘‘sensor’’ for maintaining energy homeostasis.
Unlike the effect of PCN in the liver and WAT, PCN treatment
increased Cd36 transcript level by approximately 2-fold compared
to the DMSO-treated group in BAT (Figure 7F). Accumulation of
lipids induced by a high-fat diet was blunted, indicating another
mechanism existed in BAT. The main function of BAT is to
generate heat for thermogenesis. Bartelt et al. [38] reported that
increased BAT activity enhanced triglyceride-rich lipoprotein
metabolism in mice. Exposure to low temperatures drastically
accelerated plasma clearance of triglycerides as a result of increased
uptake into BAT, which was mediated by an increase of
transmembrane receptor CD36. Although it remains to be
demonstrated for increased energy expenditure, mice with PCN
treatment had a much slower decrease in body temperature than
the control group (Figure 8A), suggesting that the activation of PXR
enhanced the thermogenesis activity inBAT. At the same time, data
from real-time PCR showed a significant increase in the transcrip-
tion of genes involved in fatty acid b-oxidization (Figure 7F) and
thermogenesis (Figure 8B), indicating increased energy expenditure
in BAT, which contributed to cleaning more lipids in BAT.
In summary, our study demonstrates that PCN-mediated PXR
activation prevented diet-induced obesity in AKR/J mice,
decreased lipid accumulation and maintained insulin sensitivity.
Additional work is needed to illustrate the precise mechanisms
through which PXR modulates energy metabolism and lipid
homeostasis. The effect of chronic activation of PXR on regulating
inflammation, another important factor associated with obesity
and type-2 diabetes, deserves attention. Considering that obesity
has become an important health problem in the recent century
with an estimated one billion people overweight and at least 300
million obese adults in the world [39], our results suggest PXR
may represent a novel therapeutic target for prevention and
treatment of obesity and type-2 diabetes. As PCN is a specific
activator for mouse PXR, caution should be taken when extending
the current conclusions to humans.
Materials and Methods
Materials
Pregnenolone-16a-carbonitrile was purchased from Sigma (St.
Louis, MO). High-fat diet (60% kJ/fat, 20% kJ/carbohydrate, 20%
kJ/protein) was purchased from Bio-serv (Frenchtown, NJ,catalog
number S3282). RNeasy Tissue kit was from Qiagen (Valencia,
CA). The SuperScriptH III First-Strand Synthesis System was
purchased from Invitrogen (Carlsbad, CA). Real-time PCR
reagents were acquired from Applied Biosystems (Foster City,
CA). An insulin assay kit was obtained from Crystal Chem
(Downers Grove, IL). Oil Red O solution was obtained from
Electron Microscopy Science (Hatfield PA). Glucometer and test
strips were purchased from LifeScan (Milpitas, CA). AKR/J mice
were purchased from the Jackson Laboratory (Bar Harbor, ME).
Animals and Treatment
All procedures performed on mice were approved by the
Institutional Animal Care and Use Committee at the University of
Georgia, Athens, Georgia. Four-week-old male AKR/J mice were
fed with high-fat diet or regular chow and received twice weekly
injections of PCN (50 mg/kg) intra-peritoneally or DMSO (carrier
solution) for 7 weeks. Animals were weighed weekly and their body
composition was determined using EchoMRI-100TM from Echo
Medical Systems (Houston, TX).
Figure 8. Effect of PCN treatment on energy expenditure of brown adipose tissue. Six-week-old male AKR/J mice were fed with high-fat
diet for two weeks with three injections per week of PCN (50 mg/kg) or DMSO (control). By the end of the feeding period, mice were exposed at 4uC
and the rectal temperature measured at different times. A, time-dependent rectal temperature. For determination of the relative mRNA level of genes
involved in thermogenesis, animals at the end of 7-week treatment were injected with PCN or carrier solution and sacrificed 4 h later. BAT tissues
were harvested and total RNA was extracted. B. Relative mRNA levels of genes involved in thermogenesis. Each data point represents the average 6
SD of 4 animals in each group. #P,0.05, ##P,0.01 compared to chow-DMSO group; *P,0.05, **P,0.01 compared to high-fat diet-DMSO group.
Abbreviations: PGC-1, peroxisome proliferator-activated receptor gamma coactivator 1 gene; Dio2, Type II iodothyronine deiodinase gene; Cidea, cell
death-inducing DNA fragmentation factor alpha-like effector A gene; and UCP, uncoupling protein gene.
doi:10.1371/journal.pone.0038734.g008
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Blood samples were collected from fasted mice. Insulin level in
the serum was measured using commercial assay kits according to
the manufacturer’s instructions. HOMA-IR was calculated as:
(fasting insulin [mU/ml] 6fasting glucose [mg/dl])/405.
Glucose Tolerance Test (GTT) and Insulin Tolerance Test
(ITT)
For GTT, mice were injected intraperitoneally with glucose at
2 g/kg body weight after fasting overnight. Blood samples were
taken at varying time points and the glucose concentrations were
measured using a glucometer. For ITT, mice fasted for 4 h and
blood glucose levels were measured after an intraperitoneal
injection of human insulin (Novolin) from Novo Nordisk
(Princeton, NJ) at 1.2 U/kg.
Histochemical Analysis
After mice were sacrificed, the liver and white and brown
adipose tissues were collected, fixed in 10% formalin, embedded in
paraffin, and sectioned at a thickness of 5 mm. H&E staining was
performed. Frozen sections (9 mm) were used for Oil Red O
staining. Microscopic examination was performed and photo-
graphs were taken under a regular light microscope.
Gene Expression Analysis by Real Time PCR
Total RNA was isolated from the mouse liver and white and
brown adipose tissues using an RNeasy kit. Two mg of total RNA
were used for the first strand cDNA synthesis as recommended by
the manufacturer (Invitrogen, Carlsbad, CA). RT-PCR was
performed using SYBR Green as an indicator on the ABI
StepOne Plus Real-Time PCR system. The final reaction mixture
contained 20 ng of cDNA, 250 nM of each primer, 10 mlo f2 x
SYBR Green PCR Master, and RNase-free water to complete the
reaction mixture volume to 20 ml. The PCR was carried out for 40
cycles at 95uC for 15 s and 60uC for 1 min. Fluorescence was read
during the reaction, allowing a continuous monitoring of the
amount of PCR product. The data were normalized to internal
control GADPH mRNA. The primer sequences employed are
summarized in Table 1.
Statistical Analysis
Statistical analysis was done by one-way ANOVA. All data are
reported as mean 6 standard deviation (SD) with statistical
significance set at P,0.05.
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